Generics: What's in a name?

Louis G. Keith*, Jaroslaw J. Oleszczuk, Catherine S. Stika, Scott Stine

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Historically, the most common intervention performed by physicians has been the writing of a prescription. Often the prescription was a combination of active agents and an inactive base. This art is no longer practiced in the United States. Currently, most prescriptions are written for specific 'drugs.' As the prescription is being written, the physician must decide to administer a brand-name or a generic equivalent. Generics are a class of medications prescribed for reasons of economy, and the physician and the patient expect that the therapeutic effect will be exactly the same as for the brand-name. Bioequivalence of specific agents can be assessed using the FDA's Orange Book. In addition to bioequivalence, many other scientific, ethical, and economic issues should be considered before a decision is made. Prescribing vigilance is necessary, because in many instances available information is often controlling or insufficient to support rational decisions. Brand-names, rather than generics, should be selected when the therapeutic index is narrow or if the likelihood of generic switching is high. The paper will discuss all aspects of the subject.

Original languageEnglish (US)
Pages (from-to)139-149
Number of pages11
JournalInternational journal of fertility and women's medicine
Volume43
Issue number3
StatePublished - 1998

Keywords

  • Bioequivalence
  • Drugs
  • Medical Economics
  • Prescribing patterns

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Generics: What's in a name?'. Together they form a unique fingerprint.

Cite this